Sagent Pharmaceuticals Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 233

Employees

  • Latest Deal Type
  • PE Growth
  • (Rumor/Speculation)

  • Latest Deal Amount
  • $175M

Sagent Pharmaceuticals General Information

Description

Developer and manufacturer of injectable pharmaceuticals in North America. The company offers a broad range of products across anti-infective, oncology and critical care indications in a variety of presentations, including single and multi-dose vials and ready-to-use pre-filled syringes and premix bags, dedicated to fulfilling the evolving needs of patients and providers alike.

Contact Information

Formerly Known As
NHS Pharmaceuticals, Sagent Holding Co.
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 1515 East Woodfield Road
  • Suite 1100
  • Schaumburg, IL 60173
  • United States
+1 (847)
Primary Industry
Pharmaceuticals
Other Industries
Medical Supplies
Parent Company
Elliminist Singapore
Corporate Office
  • 1515 East Woodfield Road
  • Suite 1100
  • Schaumburg, IL 60173
  • United States
+1 (847)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sagent Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. PE Growth/Expansion 26-Mar-2025 $175M Rumor/Speculation Profitable
9. Merger/Acquisition 28-Feb-2023 Completed Profitable
8. Merger/Acquisition 29-Aug-2016 Completed Profitable
7. IPO 19-Apr-2011 Completed Clinical Trials - General
6. Early Stage VC (Series B1) 01-Aug-2010 Completed Generating Revenue
5. Early Stage VC (Series B) 01-Mar-2010 Completed Generating Revenue
4. Debt - General 30-Jun-2009 Completed Startup
3. Early Stage VC (Series A) 15-Jun-2009 Completed Startup
2. Early Stage VC (Series A) 01-Aug-2008 $30M $83M Completed Product Development
1. Early Stage VC (Series A) 01-Sep-2007 $53M $53M Completed Product Development
To view Sagent Pharmaceuticals’s complete valuation and funding history, request access »

Sagent Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1
Series B
Series A 113,000,000 $0.000010 $1 $1 1x $1 69.83%
To view Sagent Pharmaceuticals’s complete cap table history, request access »

Sagent Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer and manufacturer of injectable pharmaceuticals in North America. The company offers a broad range of products
Pharmaceuticals
Schaumburg, IL
233 As of 2021

Mumbai, India
 

Sao Paulo, Brazil
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sagent Pharmaceuticals Competitors (10)

One of Sagent Pharmaceuticals’s 10 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evonile Pharma Private Equity-Backed Mumbai, India
Glenmark Farmacêutica Corporation Sao Paulo, Brazil
Glenmark Pharmaceuticals Corporation Mumbai, India
Dr. Reddy's Corporation Hyderabad, India
Pfizer (Vienna) Corporation Vienna, Austria
You’re viewing 5 of 10 competitors. Get the full list »

Sagent Pharmaceuticals Patents

Sagent Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120000592-A1 Label, labeling system and method of labeling for containers for drug products Inactive 01-Jul-2010
WO-2012003453-A2 Label, labeling system and method of labeling for containers for drug products Inactive 01-Jul-2010
WO-2012003453-A3 Label, labeling system and method of labeling for containers for drug products Inactive 01-Jul-2010
US-20100017747-A1 Product viewer Inactive 17-Jul-2008 G06Q30/0603

Sagent Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sagent Pharmaceuticals Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
CNF Investments PE/Buyout Minority
Capricorn Investment Group Impact Investing Minority
China Renaissance Capital Investment Venture Capital Minority
GrowthGate Capital PE/Buyout Minority
Morgan Stanley Investment Management Asset Manager Minority
You’re viewing 5 of 8 investors. Get the full list »

Sagent Pharmaceuticals Investments & Acquisitions (8)

Sagent Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Xellia Manufacturing Facility (Grove, Illinois). The deal was made on 01-Mar-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xellia Manufacturing Facility (Grove, Illinois) 01-Mar-2019 Corporate Asset Purchase Buildings and Property
Sagent Pharmaceuticals (Pharmaceutical Production Facility in Raleigh) 01-Jan-2019 Corporate Asset Purchase Buildings and Property
SterRx 21-Sep-2017 Early Stage VC Other Pharmaceuticals and Biotechnology
Teva Pharmaceutical Industries (Product Portfolio) 16-Jun-2016 Corporate Asset Purchase Buildings and Property
Omega Laboratories (Drug Delivery) 01-Oct-2014 Merger/Acquisition Drug Delivery
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Sagent Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Sagent Pharmaceuticals’s complete esg history, request access »

Sagent Pharmaceuticals FAQs

  • When was Sagent Pharmaceuticals founded?

    Sagent Pharmaceuticals was founded in 2006.

  • Where is Sagent Pharmaceuticals headquartered?

    Sagent Pharmaceuticals is headquartered in Schaumburg, IL.

  • What is the size of Sagent Pharmaceuticals?

    Sagent Pharmaceuticals has 233 total employees.

  • What industry is Sagent Pharmaceuticals in?

    Sagent Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Sagent Pharmaceuticals a private or public company?

    Sagent Pharmaceuticals is a Private company.

  • What is the current valuation of Sagent Pharmaceuticals?

    The current valuation of Sagent Pharmaceuticals is .

  • What is Sagent Pharmaceuticals’s current revenue?

    The current revenue for Sagent Pharmaceuticals is .

  • How much funding has Sagent Pharmaceuticals raised over time?

    Sagent Pharmaceuticals has raised $251M.

  • Who are Sagent Pharmaceuticals’s investors?

    CNF Investments, Capricorn Investment Group, China Renaissance Capital Investment, GrowthGate Capital, and Morgan Stanley Investment Management are 5 of 8 investors who have invested in Sagent Pharmaceuticals.

  • Who are Sagent Pharmaceuticals’s competitors?

    Evonile Pharma, Glenmark Farmacêutica, Glenmark Pharmaceuticals, Dr. Reddy's, and Pfizer (Vienna) are some of the 10 competitors of Sagent Pharmaceuticals.

  • When was Sagent Pharmaceuticals acquired?

    Sagent Pharmaceuticals was acquired on 26-Mar-2025.

  • Who acquired Sagent Pharmaceuticals?

    Sagent Pharmaceuticals was acquired by Elliminist Singapore.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process